Integrated Biopharma, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q4 of fiscal 2026, the quarter ended Jun 30, 2026 was Contract Manufacturing at $9.5 million, 97% of the total. By sales mix, the largest line in Q4 of fiscal 2026, the quarter ended Jun 30, 2026 was Contract Manufacturing at $9.5 million, 97% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
Q4 FY2026
Jun 30, 2026
|
Q3 FY2026
Mar 31, 2026
|
Q2 FY2026
Dec 31, 2025
|
Q1 FY2026
Sep 30, 2025
|
Q4 FY2025
Jun 30, 2025
|
Q3 FY2025
Mar 31, 2025
|
Q2 FY2025
Dec 31, 2024
|
Q1 FY2025
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
10
|
10
|
11
|
13
|
14
|
14
|
13
|
14
|
| Operating segments | ||||||||
| Contract Manufacturing |
9
-30.2%
share 96.8%
|
10
-27.0%
share 97.2%
|
11
-6.4%
share 96.8%
|
12
-6.2%
share 95.9%
|
14
share 95.8%
|
13
share 96.5%
|
12
share 92.5%
|
13
share 95.3%
|
| Other Nutraceutical Business |
0
-46.6%
share 3.2%
|
0
-41.8%
share 2.8%
|
0
-61.9%
share 3.2%
|
1
-18.9%
share 4.1%
|
1
share 4.2%
|
0
share 3.5%
|
1
share 7.5%
|
1
share 4.7%
|
| Sales mix | ||||||||
| Contract Manufacturing |
9
-30.2%
share 96.8%
|
10
-27.0%
share 97.2%
|
11
-6.4%
share 96.8%
|
12
-6.2%
share 95.9%
|
14
share 95.8%
|
13
share 96.5%
|
12
share 92.5%
|
13
share 95.3%
|
| Other Nutraceutical Business |
0
-46.6%
share 3.2%
|
0
-41.8%
share 2.8%
|
0
-61.9%
share 3.2%
|
1
-18.9%
share 4.1%
|
1
share 4.2%
|
0
share 3.5%
|
1
share 7.5%
|
1
share 4.7%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INBP (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hillside, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1016504
- Former names
- INTEGRATED HEALTH TECHNOLOGIES INC (until Apr 16, 2003); CHEM INTERNATIONAL INC (until May 14, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.